The largest database of trusted experimental protocols
> Disorders > Neoplastic Process > Paraganglioma

Paraganglioma

Paragangliomas are rare, usually benign tumors that develop from paraganglia, which are clusters of neuroendocrine cells found near the bodys major blood vessels and nerves.
These tumors can occur in the neck, chest, abdomen, or pelvis, and may produce excess hormones like catecholamines.
Effective research into Paragangliomas requires accessing the latest protocols, products, and advancements from literature, preprints, and patents.
PubCompare.ai is an AI-powered platform that helps locate the best resources to enhance reproducibility and accuracy in Paraganglioma research.
Discover the latest breakthroughs and optimize your Paraganglioma studdies today.

Most cited protocols related to «Paraganglioma»

Results are based in part upon data generated by TCGA Research Network (http://cancergenome.nih.gov/). We aggregated TCGA transcriptomic and RPPA data from public repositories, listed in the “Data availability” section. RNA-seq expression data were processed by TCGA at the gene level, rather than at the transcript level. Tumors spanned 32 different TCGA projects, each project representing a specific cancer type, listed as follows: LAML, acute myeloid leukemia; ACC, adrenocortical carcinoma; BLCA, bladder urothelial carcinoma; LGG, lower grade glioma; BRCA, breast invasive carcinoma; CESC, cervical squamous cell carcinoma and endocervical adenocarcinoma; CHOL, cholangiocarcinoma; CRC, colorectal adenocarcinoma (combining COAD and READ projects); ESCA, esophageal carcinoma; GBM, glioblastoma multiforme; HNSC, head and neck squamous cell carcinoma; KICH, kidney chromophobe; KIRC, kidney renal clear cell carcinoma; KIRP, kidney renal papillary cell carcinoma; LIHC, liver hepatocellular carcinoma; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; DLBC, lymphoid neoplasm diffuse large B-cell lymphoma; MESO, mesothelioma; OV, ovarian serous cystadenocarcinoma; PAAD, pancreatic adenocarcinoma; PCPG, pheochromocytoma and paraganglioma; PRAD, prostate adenocarcinoma; SARC, sarcoma; SKCM, skin cutaneous melanoma; STAD, stomach adenocarcinoma; TGCT, testicular germ cell tumors; THYM, thymoma; THCA, thyroid carcinoma; UCS, uterine carcinosarcoma; UCEC, uterine corpus endometrial carcinoma; UVM, uveal melanoma. Cancer molecular profiling data were generated through informed consent as part of previously published studies and analyzed per each original study’s data use guidelines and restrictions.
Full text: Click here
Publication 2019
4-carboxyphenylglyoxal Adenocarcinoma Adenocarcinoma of Lung Adrenocortical Carcinoma Breast Carcinoma Carcinoma, Thyroid Carcinoma, Transitional Cell Carcinosarcoma Cells Cholangiocarcinoma Chromophobia Chronic Obstructive Airway Disease Diffuse Large B-Cell Lymphoma Endocervix Endometrial Carcinoma Esophageal Cancer Familial Atypical Mole-Malignant Melanoma Syndrome Gene Expression Profiling Genes Glioblastoma Multiforme Glioma Hepatocellular Carcinomas Hypernephroid Carcinomas Kidney Leukemia, Myelocytic, Acute Lung Lymph Malignant Neoplasms Mesothelioma Neck Neoplasms Ovary Pancreas Paraganglioma Pheochromocytoma Prostate Renal Cell Carcinoma RNA-Seq Sarcoma Serous Cystadenocarcinoma Squamous Cell Carcinoma Squamous Cell Carcinoma of the Head and Neck Stomach Testicular Germ Cell Tumor Thymoma Urinary Bladder Uterus Uveal melanoma X-Ray Photoelectron Spectroscopy
This study was performed as a prospective case series and subjects were recruited from a dedicated neuroendocrine tumour clinic and a national paediatric and adult wild-type (PAWS) GIST clinic in Cambridge University NHS Foundation Trust. Suitable patients were identified based on SDHx germline status, suspicious clinical phenotype (metastatic PPGL, paraganglioma or wtGIST) and/or immunohistochemistry of tumour tissue showing absent SDHB immunostaining. A minimum tumour size threshold of 1.5cm was applied for inclusion into the study. All participants gave written informed consent and the study was approved by Cambridge South Research Ethics Committee.
Publication 2018
Adult Ethics Committees, Research Gastrointestinal Stromal Tumors Germ Line Immunohistochemistry Neoplasms Neuroendocrine Tumors Paraganglioma Patients Phenotype SDHB protein, human Tissues
To create OMCD, we used the LAMP software bundle (Linux, Apache 2, MySQL 5.0, and PHP) and Hypertext Markup Language (HTML), as described previously [8 (link)] and made the resulting website accessible to researchers across the globe. To host OMCD’s web application, we chose an Apache web server. To generate the user interface and enable communication with the MySQL database at the back end, we chose PHP, given its database-driven architecture that was designed for incorporation of additional information. Normalized expression data, statistical results, and annotation data are all stored in OMCD. To facilitate data retrieval and selection of different criteria for analysis, we designed a user-friendly graphic interface.
To construct the content of OMCD, we downloaded from TCGA the miRNA expression data of 9656 patients (represented by 8993 tumor samples and 663 control samples of normal tissue with 33 different cancer types (https://gdc.nci.nih.gov; Table 1). We used a 2-group t test to determine which miRNAs were differentially expressed between 1) control and tumor samples, for a given cancer type, 2) a cancer patient’s control sample, as compared with all other patients’ available control samples, and 3) a cancer patient’s tumor sample, as compared with all other patients’ available tumor samples. It can be noted that each of our 3 analyses had a different statistical power, which may account for the absence of a given miRNA from a specific dataset.

Number of patients in the OncomiR Cancer Database (OMCD), by cancer type

Cancer Type (TCGA Code)Total number of samplesTumorNormal
Breast invasive carcinoma [BRCA]86978287
Brain Lower Grade Glioma [LGG]5305300
Thyroid carcinoma [THCA]57351459
Prostate adenocarcinoma [PRAD]55149952
Ovarian serous cystadenocarcinoma [OV]4954950
Head and Neck squamous cell carcinoma [HNSC]53248844
Lung adenocarcinoma [LUAD]50445846
Skin Cutaneous Melanoma [SKCM]4534512
Uterine Carcinosarcoma [UCS]45041832
Bladder Urothelial Carcinoma [BLCA]43641719
Stomach adenocarcinoma [STAD]45040446
Liver hepatocellular carcinoma [LIHC]42637551
Lung squamous cell carcinoma [LUSC]38834345
Cervical squamous cell carcinoma and endocervical adenocarcinoma [CESC]3133103
Kidney renal papillary cell carcinoma [KIRP]32629234
Colon adenocarcinoma [COAD]2802728
Sarcoma [SARC]2632630
Kidney renal clear cell carcinoma [KIRC]33226171
Esophageal carcinoma [ESCA]20018713
Pheochromocytoma and Paraganglioma [PCPG]1871843
Pancreatic adenocarcinoma [PAAD]1831794
Testicular Germ Cell Tumors [TGCT]1561560
Thymoma [THYM]1261242
Rectum adenocarcinoma [READ]97943
Mesothelioma [MESO]87870
Uveal Melanoma [UVM]80800
Adrenocortical carcinoma [ACC]79790
Kidney Chromophobe [KICH]916625
Uterine Corpus Endometrial Carcinoma [UCEC]57570
Diffuse Large B-cell Lymphoma [DLBC]47470
FFPE Pilot Phase II [FPPP]45450
Cholangiocarcinoma [CHOL]45369
Glioblastoma multiforme [GBM]505
Total96568993663
Full text: Click here
Publication 2018
4-carboxyphenylglyoxal Adenocarcinoma Carcinoma Carcinoma, Transitional Cell Carcinosarcoma Chromophobia Chronic Obstructive Airway Disease Endocervix Endometrial Carcinoma Eye Glioma Hepatocellular Carcinomas Hypernephroid Carcinomas Malignant Neoplasms Melanoma MicroRNAs Neck Neoplasms Paraganglioma Patients Renal Cell Carcinoma Reticulosarcoma Serous Cystadenocarcinoma Squamous Cell Carcinoma Testicular Germ Cell Tumor Tissues Tumor, Germ Cell X-Ray Photoelectron Spectroscopy
Aligned RNA-seq bam files were analyzed using the ISB Cancer Genomics Cloud (https://isb-cgc.appspot.com/). These 33 cancer types included in this study are adrenocortical carcinoma [ACC], bladder urothelial carcinoma [BLCA], brain lower grade glioma [LGG], breast invasive carcinoma [BRCA], cervical squamous cell carcinoma and endocervical adenocarcinoma [CESC], cholangiocarcinoma [CHOL], colon adenocarcinoma [COAD], esophageal carcinoma [ESCA], glioblastoma multiforme [GBM], head and neck squamous cell carcinoma [HNSC], kidney chromophobe [KICH], kidney renal clear cell carcinoma [KIRC], kidney renal papillary cell carcinoma [KIRP], acute myeloid leukemia [LAML], liver hepatocellular carcinoma [LIHC], lung adenocarcinoma [LUAD], lung squamous cell carcinoma [LUSC], lymphoid neoplasm diffuse large B cell lymphoma [DLBC], mesothelioma [MESO], ovarian serous cystadenocarcinoma [OV], pancreatic adenocarcinoma [PAAD], pheochromocytoma and paraganglioma [PCPG], prostate adenocarcinoma [PRAD], rectum adenocarcinoma [READ], sarcoma [SARC], skin cutaneous melanoma [SKCM], stomach adenocarcinoma [STAD], testicular germ cell tumors [TGCT], thymoma [THYM], thyroid carcinoma [THCA], uterine carcinosarcoma [UCS], uterine corpus endometrial carcinoma [UCEC], and uveal melanoma [UVM]. The sample set consists of 10,337 total TCGA samples, 9,624 tumor samples, and 713 normal samples.
Level-3 gene expression (RSEM) and segment-based copy number data were downloaded from Broad GDAC firehose (https://gdac.broadinstitute.org) (version: 2016_01_28). Gene-based copy number data were obtained by intersecting with RefSeq gene annotation bed file (version: 2013-07-27). Mutation calls were provided by the Multi-Center Mutation Calling in Multiple Cancers (MC3) working group within TCGA (Key Resources Table; Ellrott et al., 2018 ).
Full text: Click here
Publication 2018
Adenocarcinoma Adenocarcinoma of Lung Adrenocortical Carcinoma Brain Breast Carcinoma Carcinoma, Thyroid Carcinoma, Transitional Cell Carcinosarcoma Cells Cholangiocarcinoma Chromophobia Colon Adenocarcinomas Diffuse Large B-Cell Lymphoma Endocervix Endometrial Carcinoma Esophageal Cancer Familial Atypical Mole-Malignant Melanoma Syndrome Gene Annotation Gene Expression Genes Glioblastoma Multiforme Glioma Hepatocellular Carcinomas Hypernephroid Carcinomas Kidney Leukemia, Myelocytic, Acute Lung Lymph Malignant Neoplasms Mesothelioma Mutation Neck Neoplasms Ovary Pancreas Paraganglioma Pheochromocytoma Prostate Rectum Renal Cell Carcinoma RNA-Seq Sarcoma Serous Cystadenocarcinoma Squamous Cell Carcinoma Squamous Cell Carcinoma of the Head and Neck Stomach Testicular Germ Cell Tumor Thymoma Urinary Bladder Uterus Uveal melanoma
Continuous variables are expressed as the means ± SD and were analysed by independent t-tests for normally distributed data or Mann-Whitney tests for non-normally distributed data. For the qualitative variables, the Chi square test was used to compare the sample proportions of the two groups. Generalized estimating equations based on a binary logistic regression model were used to determine whether lesion type (retroperitoneal extra-adrenal paragangliomas or schwannomas) was associated with any of the individual binary factors. In this context, stepwise variable selection was performed to determine whether the combination of two or more of the aforementioned imaging features represented a significant independent predictor of schwannoma or paraganglioma. These tests were performed separately for each reader. Kappa coefficients were not used for this determination because the very high prevalence rates of certain imaging features for many of the binary factors was expected to produce misleadingly low values [8 (link), 10 ]. All reported p values are two-sided and considered statistically significant when less than 0.05. SPSS version 19.0 software (IBM Corporation, Armonk, NY, USA) was used for all computations.
Full text: Click here
Publication 2018
Extra-Adrenal Paraganglioma Neurilemmoma Paraganglioma Retroperitoneal Space

Most recents protocols related to «Paraganglioma»

Manifests containing fragments per kilobase per million (FPKM) normalized RNA-seq data from 34 TCGA cohorts – Acute Myeloid Leukemia - (TCGA-LAML), Adrenocortical carcinoma (TCGA-ACC), Bladder Urothelial Carcinoma (TCGA-BLCA), Glioblastoma multiforme and Brain Lower Grade Glioma and (TCGA-GBMLGG), Breast Invasive Carcinomas (TCGA-BRCA), Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma (TCGA-CESC), Cholangiocarcinoma (TCGA-CHOL), Chronic Myelogenous Leukemia (TCGA-LCML), Colon Adenocarcinoma (TCGA-COAD), Esophageal Carcinoma (TCGA-ESCA), Head and Neck Squamous Cell Carcinoma (TCGA-HNSC), pan-Kidney Cancer (TCGA-KIPAN), Liver Hepatocellular Carcinoma (TCGA-LIHC), Lung Adenocarcinoma (TCGA-LUAD), Lung Squamous Cell Carcinoma (TCGA-LUSC), Lymphoid Neoplasm Diffuse Large B-cell Lymphoma (TCGA-DLBC), Mesothelioma (TCGA-MESO), Ovarian Serous Cystadenocarcinoma (TCGA-OV), Pancreatic Adenocarcinoma (TCGA-PAAD), Pheochromocytoma and Paraganglioma (TCGA-PCPG), Prostate Adenocarcinoma (TCGA-PRAD), Rectum Adenocarcinoma (TCGA-READ), Sarcoma (TCGA-SARC), Skin Cutaneous Melanoma (TCGA-SKCM), Stomach Adenocarcinoma (TCGA-STAD), Testicular Germ Cell Tumors (TCGA-TGCT), Thymoma (TCGA-TGCT), Thyroid Carcinoma (TCGA-THCA), Uterine Carcinosarcoma (TCGA-USC), Uterine Corpus Endometrial Carcinoma (TCGA-UCES), Uveal Melanoma (TCGA-UVM) were downloaded from the Broad Institute GDAC (TCGA data version 20150601). Patients were then sorted by increasing B7-H3 expression in each cohort.
Full text: Click here
Publication 2023
4-carboxyphenylglyoxal Adenocarcinoma Adenocarcinoma of Lung Adrenocortical Carcinoma Brain Breast Carcinoma Cancer of Kidney Carcinoma, Thyroid Carcinoma, Transitional Cell Carcinosarcoma Cholangiocarcinoma Chronic Obstructive Airway Disease Colon Adenocarcinomas Diffuse Large B-Cell Lymphoma Endocervix Endometrial Carcinoma Esophageal Cancer Familial Atypical Mole-Malignant Melanoma Syndrome Glioblastoma Multiforme Glioma Hepatocellular Carcinomas Leukemia, Myelocytic, Acute Leukemias, Chronic Granulocytic Lung Lymph Mesothelioma Neck Neoplasms Ovary Pancreas Paraganglioma Patients Pheochromocytoma Prostate Rectum RNA-Seq Sarcoma Serous Cystadenocarcinoma Squamous Cell Carcinoma Squamous Cell Carcinoma of the Head and Neck Stomach Testicular Germ Cell Tumor Thymoma Urinary Bladder Uterus Uveal melanoma X-Ray Photoelectron Spectroscopy
The TCGA Research Network (https://portal.gdc.cancer.gov/) has analyzed clinical and molecular data from over 10,000 oncology patients in 33 countries, covering 33 different tumor types and over 10,000 oncology patients. Transcriptomic RNA-seq data for 33 cancers were extracted from TCGA database. 33 cancer types were included: adrenocortical carcinoma (ACC), bladder urothelial carcinoma (BLCA), breast invasive carcinoma (BRCA), colon adenocarcinoma (COAD), lymphoid neoplasm diffuse large B cell lymphoma (DLBC), esophageal carcinoma (ESCA), glioblastoma multiforme (GBM), head and neck squamous cell carcinoma (HNSC), kidney chromophobe (KICH), kidney renal clear cell carcinoma (KIRC), kidney renal papillary cell carcinoma (KIRP), acute myeloid leukemia (LAML), brain lower grade glioma (LGG), liver hepatocellular carcinoma (LIHC), lung adenocarcinoma (LUAD), lung squamous cell carcinoma (LUSC), ovarian serous cystadenocarcinoma (OV), pancreatic adenocarcinoma (PAAD), prostate adenocarcinoma (PRAD), pheochromocytoma and paraganglioma (PCPG), rectum adenocarcinoma (READ), skin cutaneous melanoma (SKCM), stomach adenocarcinoma (STAD), testicular germ cell tumors (TGCT), thyroid carcinoma (THCA), thymoma (THYM), uterine corpus endometrial carcinoma (UCEC), cholangiocarcinoma (CHOL), cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), mesothelioma (MESO), sarcoma (SARC), uveal melanoma (UVM), and uterine carcinosarcoma (UCS).
Full text: Click here
Publication 2023
Adenocarcinoma Adenocarcinoma of Lung Adrenocortical Carcinoma Brain Breast Carcinoma Carcinoma, Thyroid Carcinoma, Transitional Cell Carcinosarcoma Cells Cholangiocarcinoma Chromophobia Colon Adenocarcinomas Diffuse Large B-Cell Lymphoma Endocervix Endometrial Carcinoma Esophageal Cancer Familial Atypical Mole-Malignant Melanoma Syndrome Gene Expression Profiling Glioblastoma Multiforme Glioma Hepatocellular Carcinomas Hypernephroid Carcinomas Kidney Leukemia, Myelocytic, Acute Lung Lymph Malignant Neoplasms Mesothelioma Neck Neoplasms Ovary Pancreas Paraganglioma Patients Pheochromocytoma Prostate Rectum Renal Cell Carcinoma RNA-Seq Sarcoma Serous Cystadenocarcinoma Squamous Cell Carcinoma Squamous Cell Carcinoma of the Head and Neck Stomach Testicular Germ Cell Tumor Thymoma Urinary Bladder Uterus Uveal melanoma
RNA sequencing (RNA-seq) data were downloaded from genomic data commons (GDC) using TCGA PanCancer publication (5 (link)) (https://gdc.cancer.gov/about-data/publications/PanCan-CellOfOrigin: EBPlusPlusAdjustPANCAN_IlluminaHiSeq_RNASeqV2.geneExp.tsv), collapsed to the gene level. Tumors were first removed according to TCGA annotation of low-quality samples (ref. 10 (link); n = 10,344). Tumor subtypes were determined from tumor-specific TCGA publications including cervical squamous cell carcinoma than endocervical adenocarcinoma (CESC; ref. 14 (link)), pheochromocytoma and paraganglioma (PCPG; ref. 15 (link)), head and neck squamous cell carcinoma (HNSC; ref. 16 (link)), thymoma (THYM; ref. 17 (link)), pancreatic adenocarcinoma (PAAD; ref. 18 (link)), BLCA (19 (link)), kidney renal clear cell carcinoma (KIRC; ref. 20 (link)), ovarian serous cystadenocarcinoma (OV; ref. 21 (link)), lung squamous carcinoma (LUSC) (22 (link)), lung adenocarcinoma (LUAD; ref. 23 (link)), skin cutaneous melanoma (SKCM; ref. 24 (link)), kidney renal papillary cell carcinoma (KIRP; ref. 25 (link)), prostate adenocarcinoma (PRAD; ref. 26 (link)), and liver hepatocellular carcinoma (LIHC; ref. 27 (link)). For all other subtypes, subtype descriptions from the PanCancer Atlas Oncogenic Signaling publication (10 (link)) were utilized (Supplementary Table S1). Tumors represented 31 tumor types (Supplementary Table S3), with 23 harboring subtypes (range: 2–9, median: 4).
Full text: Click here
Publication 2023
4-carboxyphenylglyoxal Adenocarcinoma Adenocarcinoma of Lung Cells Endocervix Familial Atypical Mole-Malignant Melanoma Syndrome Genes Genome Hepatocellular Carcinomas Hypernephroid Carcinomas Lung Malignant Neoplasms Neck Neoplasms Neoplastic Cell Transformation Ovary Pancreas Paraganglioma Pheochromocytoma Prostate Renal Cell Carcinoma Serous Cystadenocarcinoma Squamous Cell Carcinoma Squamous Cell Carcinoma of the Head and Neck Thymoma
All patients underwent a fully preoperative evaluation, including general clinical assessment, haematological, cardiovascular and pneumologic evaluations. Although MRI is generally considered the best choice in the evaluation of parapharyngeal tumors as it usually provides better information about soft tissues compared to TC scan, we performed both MRI (76 patients) and CT (51 patients) preoperative examinations in many cases, as they could be complementary in tumor characteristics evaluation, particularly in potentially malignant lesions. MRI was often more able to precisely define the relationship between tumor and surrounding great vessels, especially internal carotid artery (ICA) and to define more accurately the nature of some specific neoplasms (e.g., pleomorphic adenomas, paragangliomas). On the other hand, CT scans provided more accurate information on bony invasion, erosion or calcification within tumors. A selective angiography was preoperatively proposed for all enhancing lesions (37 patients) to favor differential diagnosis between neurogenic and vascular tumors. Ultrasound-assisted fine needle aspiration (USgFNAC) was performed when malignancy was clinically or radiologically suspected (25 patients), with the exception of vascular lesions or in case of inadequate ultrasound targeting or lesion proximity with major vessels. Moreover, in patients who received malignant diagnosis, FDG-PET has been performed as a useful method to detect distant metastasis not only in pre-operative assessment to support treatment planning, but also in mid and late post-operative follow-up. Incisional transoral or transcervical biopsy was rarely considered beneficial in our patients, thus it was performed only in patients who were not candidates for surgery, to obtain the histological diagnosis (3 patients).
Full text: Click here
Publication 2023
Angiography Aspiration Biopsy, Fine-Needle Biopsy Blood Vessel Bones Cardiovascular System Diagnosis Differential Diagnosis Internal Carotid Arteries Malignant Neoplasms Mixed Salivary Gland Tumor Neoplasm Metastasis Neoplasms Neoplasms, Vascular Tissue Neurogenesis Operative Surgical Procedures Paraganglioma Patients Physical Examination Radionuclide Imaging Tissues Tumoral Calcinosis Ultrasonics X-Ray Computed Tomography
We performed a monocentric, retrospective observational study, on a total of 1800 patients affected by cervical tumors, who underwent to diagnostic and therapeutic workout in our Centre between 2002 and 2021. Patients were identified considering a list of International Classification of Disease (ICD) codes that refer to neoplasms involving PPS. According to many inclusion criteria of Riffat et al., (2014) [1 (link)], we selected 98 patients, 50 males and 48 females, ranging from 20 months to 86 years of age. More specifically, only tumors located in PPS were considered eligible, while metastatic neoplasms involving PPS but originating from other anatomical regions were excluded. Among the salivary neoplasms of the parotid deep lobe, we included only those located in the retroangulomandibular neck region. Among the carotid paragangliomas, we considered eligible only those located above the posterior belly of the digastric muscle. Cases lacking an accurate description of preoperative diagnostic techniques, adequate report on the tumor characteristics, surgical approach, histological subtypes diagnosis, postoperative outcome or complications accurate report were excluded. Diagnostic workout revealed bilateral neoplasms in two patients, so a total of 100 PPS tumors, ranging from 16 to 83 mm maximum diameter and involving pre or retro stiloyd parapharingeal spaces, were studied. Compressively, 96 cases underwent surgery. One patient was exclusively treated with embolization and three more cases with an elective radio-chemiotheraphy protocol after trans cervical or endoscopic biopsy to confirm histological diagnosis. surgical planning was performed according to tumor location, histology, dimensions, imaging data, surrounding anatomic features and clinical findings.
Full text: Click here
Publication 2023
Biopsy Body Regions Carotid Arteries Diagnosis Embolization, Therapeutic Endoscopy Females Males Muscle, Back Neck Neoplasm Metastasis Neoplasms Neoplasms by Site Operative Surgical Procedures Paraganglioma Parotid Neoplasms Patients Preoperative Procedure Signs and Symptoms Therapeutics Uterine Cervical Neoplasm

Top products related to «Paraganglioma»

Sourced in United States, China, Germany, United Kingdom, Spain, Australia, Italy, Canada, Switzerland, France, Cameroon, India, Japan, Belgium, Ireland, Israel, Norway, Finland, Netherlands, Sweden, Singapore, Portugal, Poland, Czechia, Hong Kong, Brazil
The MiSeq platform is a benchtop sequencing system designed for targeted, amplicon-based sequencing applications. The system uses Illumina's proprietary sequencing-by-synthesis technology to generate sequencing data. The MiSeq platform is capable of generating up to 15 gigabases of sequencing data per run.
Sourced in United States
The HPA002868 is a laboratory equipment product manufactured by Merck Group. It is designed for use in various scientific research and analytical applications. The core function of this equipment is to perform specific tasks required in laboratory settings. However, a detailed and unbiased description of the product's features and capabilities is not available at this time.
Sourced in United States, China, Japan, Germany, United Kingdom, Canada, France, Italy, Australia, Spain, Switzerland, Netherlands, Belgium, Lithuania, Denmark, Singapore, New Zealand, India, Brazil, Argentina, Sweden, Norway, Austria, Poland, Finland, Israel, Hong Kong, Cameroon, Sao Tome and Principe, Macao, Taiwan, Province of China, Thailand
TRIzol reagent is a monophasic solution of phenol, guanidine isothiocyanate, and other proprietary components designed for the isolation of total RNA, DNA, and proteins from a variety of biological samples. The reagent maintains the integrity of the RNA while disrupting cells and dissolving cell components.
Sourced in United States, Germany, United Kingdom, China, Italy, Sao Tome and Principe, France, India, Macao, Israel, Singapore, Switzerland, Senegal, Hungary, Brazil, Ireland, Australia, Japan, Czechia
FITC is a fluorescent dye used in various laboratory applications. It is a green-fluorescent dye that is commonly used for labeling and detecting biomolecules, such as proteins, antibodies, and nucleic acids. FITC emits light in the green region of the visible spectrum when excited by a suitable light source.
Sourced in United States
R is an open-source software environment for statistical computing and graphics. It provides a wide variety of statistical and graphical techniques, including linear and nonlinear modeling, classical statistical tests, time-series analysis, classification, clustering, and others. R is widely used in academic and research communities for data analysis and visualization.
Sourced in United States
The NextSeq 500/550 is a benchtop sequencing instrument designed for a wide range of applications, including whole-genome sequencing, targeted resequencing, gene expression profiling, and small RNA analysis. The instrument utilizes Illumina's sequencing-by-synthesis technology to generate high-quality sequencing data.
Sourced in United States, United Kingdom, Japan, China
SPSS software version 20.0 is a statistical analysis software package developed by IBM. It is designed to handle a wide range of data analysis tasks, including data management, statistical modeling, and reporting. The software provides a comprehensive set of tools for data manipulation, analysis, and visualization, making it a popular choice for researchers, analysts, and decision-makers across various industries.
Sourced in United States, Japan, United Kingdom, Netherlands
The LOGIQ 7 is a versatile diagnostic imaging system designed for clinical applications. It offers advanced imaging capabilities to healthcare professionals, providing them with the tools necessary for accurate and efficient patient care.
Sourced in United States
The Infinium MethylationEPIC array is a lab equipment product by Illumina. It is a comprehensive DNA methylation profiling beadchip designed for genome-wide analysis of DNA methylation patterns.
Sourced in United States
SPSS Statistics software version 23 is a data analysis tool that allows users to manage, analyze, and visualize data. It provides a wide range of statistical techniques and features for data manipulation, regression analysis, and hypothesis testing.

More about "Paraganglioma"

Paragangliomas are rare, usually benign neuroendocrine tumors that originate from paraganglia, which are clusters of hormone-producing cells found near the body's major blood vessels and nerves.
These tumors can develop in the neck, chest, abdomen, or pelvis, and may cause excess production of catecholamines like adrenaline and noradrenaline.
Effective research into Paragangliomas requires accessing the latest protocols, products, and advancements from scientific literature, preprints, and patents.
PubCompare.ai is an AI-powered platform that helps researchers locate the best resources to enhance reproducibility and accuracy in Paraganglioma studies.
Paraganglioma research may involve the use of advanced genomic and molecular techniques, such as the MiSeq platform for DNA sequencing, the HPA002868 antibody for protein detection, and the TRIzol reagent for RNA extraction.
Fluorescence-based assays like FITC may be employed, and statistical analysis can be performed using R software or SPSS.
The latest advancements in Paraganglioma research can be further explored using the NextSeq 500/550 instrument for high-throughput sequencing, the LOGIQ 7 for medical imaging, and the Infinium MethylationEPIC array for DNA methylation analysis.
SPSS Statistics software version 23 can be utilized for comprehensive data analysis.
Discover the latest breakthroughs and optimize your Paraganglioma studies today with the intelligent comparison tools provided by PubCompare.ai.
Enhance reproducibility and accuracy in your research with this AI-powered platform that helps you locate the best protocols, products, and resources from scientific literature, preprints, and patents.